M&D

M&D Pharmatech is a clinical-stage biotechnology company based in South Korea that specializes in developing first-in-class and best-in-class therapeutics for metabolic and neurodegenerative diseases. The company's primary focus is on multi-targeting peptide agonists, particularly those targeting the GLP-1, GIP, and Glucagon receptors for the treatment of obesity, diabetes, and NASH. Additionally, M&D Pharmatech is advancing a pipeline of small molecule inhibitors for neurodegenerative conditions like Parkinson's and Alzheimer's disease. By leveraging its proprietary drug discovery platforms, the company aims to address significant unmet medical needs through innovative molecular engineering.